Luqa Pharma, a Shanghai dermatology and aesthetics company, acquired greater China rights to a novel topical antibiotic aimed at impetigo from Barcelona's Ferrer. The two companies will collaborate to obtain China approval of Ozenoxacin (known by trade names Ozanex, Dubine and Xepi), which is already approved in the US and EU. Depending on the outcome of the regulatory process, Luqa could exercise a licensing option for further development and commercialization of Ozenoxacin. More details....
Share this with colleagues:
Original Article: Luqa Acquires China Rights to Topical Antibiotic from Spain's Ferrer